Association between different atherogenic and insulin resistance indices and infertility in polycystic ovary syndrome patients Authors: Kasra Jafari, Nazanin Azmi-Naei, Nooshan Tajik, Ashraf Moini, Amene Abiri, Ricardo Cobucci, Ricardo Cobucci, Ricardo Cobucci Published: 2026 ABSTRACT BackgroundThis study aimed to assess the association between multiple atherogenic and insulin resistance indices—including TyG, TyG-BMI, AIP, TG-HDL, and METS-IR—and infertility in women with PCOS, and to evaluate their clinical utility.MethodsIn this cross-sectional study, we analyzed data from 669 sexually active women aged 18–45 with PCOS treated at a tertiary center in Iran (2021–2023). We compared infertile women with PCOS (≥12 months unsuccessful conception, n = 274) to fertile women with PCOS (n = 395). Logistic regression, restricted cubic spline, and receiver operating characteristic (ROC) analysis were used to assess associations and predictive performance.ResultsInfertile women had significantly worse metabolic profiles across all indices (P < 0.001). AIP showed the largest point estimate of association (adjusted OR = 9.065, 95% CI: 1.722–47.721). TG-HDL showed a significant non-linear relationship, with ORs rising steeply up to a ratio of ~2.5. Predictive ability was modest, with AUCs ranging from 0.598 (TyG-BMI) to 0.625 (AIP, TG-HDL).ConclusionSeveral metabolic indices, particularly AIP, are associated with infertility in women with PCOS, though their standalone predictive utility remains limited. Introduction With global prevalence rates estimated between 4% and 21%, polycystic ovary syndrome (PCOS) represents one of the most common endocrine disorders in women of reproductive age [1]. Characterized by clinical features such as androgen excess, ovulatory dysfunction, and polycystic ovarian morphology, PCOS is a major contributor to female infertility, accounting for approximately 80% of anovulatory infertility cases [2]. Insulin resistance (IR) plays a well-established role in infertility and is closely linked to PCOS [3,4]. IR leads to hyperinsulinemia, which increases ovarian androgen production and disrupts folliculogenesis, resulting in anovulation [5]. It also alters the hypothalamic-pituitary-ovarian axis by raising luteinizing hormone relative to follicle-stimulating hormone, further impairing ovulatory function [6]. Additionally, IR activates the PI3K/AKT pathway in the endometrium, causing abnormal proliferation and reduced receptivity. These mechanisms collectively contribute to infertility [7]. Adipose tissue functions not only as an energy reservoir but also as a significant endocrine organ capable of producing and metabolizing sex hormones, including androgens. It serves as a site where androgens, estradiol, and dehydroepiandrosterone are converted into various estrogens, influencing reproductive function [8]. Furthermore, elevated lipid levels in the ovarian environment can disrupt oocyte maturation, potentially leading to infertility [9]. The metabolic score for insulin resistance (METS-IR) is a practical marker estimating IR using BMI, triglycerides, and fasting glucose [10]. It reflects important metabolic changes and is associated with conditions like type 2 diabetes, cardiovascular diseases, and inflammatory disorders such as psoriasis [11–13]. METS-IR is also linked to PCOS, suggesting its value as a non-invasive tool to assess metabolic risk in affected women [14]. Lipid-based markers have proven valuable in assessing insulin resistance and metabolic dysfunction in women with PCOS. Elevated triglyceride-to-HDL ratios, common in these patients, are linked to increased cardiometabolic risk [15,16]. Indices like TyG and TyG-BMI, which combine triglycerides with glucose or BMI, serve as practical tools for detecting early metabolic dysfunction, including prediabetes [17]. Considering adipose tissue’s role in insulin resistance via adipokines and inflammation, these markers may enhance metabolic risk evaluation alongside METS-IR in PCOS [18]. Although several studies have explored the association between IR related indices and female infertility, most have been conducted in the general population using large survey datasets such as NHANES, without focusing on women with PCOS, a group with a distinct metabolic and reproductive profile. Moreover, prior research has typically evaluated single indices in isolation, with limited assessment of non-linear associations or predictive performance comparison, and without considering the atherogenic index of plasma (AIP). To address these gaps, the present study aimed to comprehensively evaluate and compare multiple atherogenic and IR indices (including TyG, TyG-BMI, AIP, TG–HDL, and METS-IR) in relation to infertility specifically among women with PCOS. In addition, we assessed potential non-linear relationships and the discriminatory performance of these indices to clarify their clinical relevance within this high-risk population. Materials and methods Study design and participants This cross-sectional study utilized medical records of all patients diagnosed with polycystic ovary syndrome (PCOS) based on the Rotterdam 2003 criteria [19] at Arash Women’s Hospital in Tehran, Iran. Data from March 1st, 2021, to December 31st, 2023, were extracted for analysis (all data extracted on February 20th, 2024). The authors did not have access to information that could identify individual participants during or after data collection Eligibility criteria The study included sexually active women aged 18–45 diagnosed with PCOS. Exclusion criteria were: (1) non-sexually active women, (2) those with current or previous cancer diagnoses, and (3) cases with male factor infertility (as recorded in medical files). Measurements and tools Blood samples were collected after an overnight fast of at least 8–12 hours. Serum levels of TG, HDL, LDL, and FBS were measured using standard methods with commercially available kits (Pars Azmoon, Tehran, Iran), according to the manufacturer’s instructions and routine laboratory quality-control procedures. Anthropometric measurements were obtained by trained clinical staff. Body weight was measured using a Seca 813 digital scale (accurate to 50 g) with participants wearing light clothing and no shoes, and height was measured using a wall-mounted stadiometer. Infertility status was determined based on documentation in medical records, defined as failure to achieve a clinical pregnancy after at least 12 months of regular unprotected intercourse. This information was recorded during routine clinical evaluations by treating gynecologists and was not based solely on self-report. Women with documented male factor infertility were excluded. Other major female causes of infertility unrelated to PCOS (such as known uterine anomalies, tubal obstruction, or premature ovarian insufficiency) were assessed when available in the medical records; however, infertility was classified as all-cause infertility within a PCOS population. PCOS was diagnosed by experienced gynecologists based on the revised 2003 Rotterdam criteria. According to these criteria, PCOS was defined by the presence of at least two of the following three features: (1) oligo- or anovulation, (2) clinical and/or biochemical signs of hyperandrogenism, and (3) polycystic ovarian morphology on ultrasound, after exclusion of other etiologies. Several metabolic indices were calculated using fasting laboratory values and anthropometric measurements. Body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared: The Triglyceride-Glucose (TyG) index was calculated as the natural logarithm of the product of fasting triglycerides and fasting blood glucose divided by two: To further enhance the metabolic predictive capacity, the TyG-BMI index was calculated by multiplying the TyG index by the BMI: The AIP was determined by taking the base-10 logarithm of the ratio of triglycerides to HDL cholesterol: The triglyceride-to-HDL cholesterol ratio (TG-HDL) was calculated by dividing the serum triglyceride level by HDL cholesterol: Finally, the Metabolic Score for Insulin Resistance (METS-IR) was calculated using the following validated formula: Ethical considerations This study received ethical approval from the Tehran University of Medical Sciences ethics committee (IR.TUMS.MEDICINE.REC.1402.582, approval date: 2024-01-21). All procedures complied with Iran’s national guidelines for medical research. Statistical analysis Continuous variables are presented as mean ± standard deviation (SD) and were compared using independent t-tests. Categorical variables were analyzed using chi-square tests. We evaluated associations using three sequential logistic regression models: (1) an unadjusted model, (2) a model adjusted for age, and (3) a model adjusted for age, BMI, and LDL, with covariate selection informed by a literature review. For linear associations, we used standard binary logistic regression, while non-linear relationships were modeled using restricted cubic splines (RCSs) with four knots. We assessed the predictive performance of each atherogenic index through receiver operating characteristic (ROC) curve analysis. All analyses were performed in R version 4.5.0, with statistical significance defined as α = 0.05 (two-tailed). Results Participants characteristics Of the initially 1,004 assessed women, 335 women were excluded according to the exclusion criteria, and 669 women were included in the final analysis, of whom 274 (40.96%) were classified as infertile and 395 (59.04%) as fertile. The mean age of participants was 32.33 ± 5.69 years, with infertile women being significantly older than fertile women (33.11 ± 5.66 vs. 31.79 ± 5.65 years, P = 0.003). Anthropometric and metabolic parameters showed significant differences between the two groups. Infertile women had a significantly higher body mass index (BMI) compared to fertile women (26.02 ± 4.95 vs. 24.59 ± 4.19 kg/m², P < 0.001). Although serum Anti-Müllerian Hormone (AMH) levels were lower in infertile women (4.58 ± 3.89 ng/mL) compared to fertile women (5.11 ± 4.68 ng/mL), this difference was not statistically significant (P = 0.122). Serum vitamin D levels were similar between groups (28.50 ± 14.97 vs. 28.75 ± 14.25 ng/mL, P = 0.829). Regarding lipid profiles and glucose metabolism, infertile women had significantly higher levels of triglycerides (123.60± 43.20 vs. 108.95 ± 41.99 mg/dL, P < 0.001), low-density lipoprotein (LDL) cholesterol (105.35 ± 29.44 vs. 98.03± 58.08 mg/dL, P < 0.001), and fasting blood sugar (FBS) (99.32 ± 36.98 vs. 92.09 ± 9.76 mg/dL, P < 0.001). Conversely, high-density lipoprotein (HDL) cholesterol levels were lower in the infertile group (40.09 ± 5.10 vs. 42.13 ± 4.71 mg/dL, P < 0.001). Infertile women also demonstrated significantly higher values for all examined atherogenic and insulin resistance indices, including the TyG (8.64 ± 0.45 vs. 8.45 ± 0.40, P < 0.001), TyG-BMI (226.45 ± 54.48 vs. 209.24 ± 44.80, P < 0.001), AIP (0.47 ± 0.19 vs. 0.39 ± 0.19, P < 0.001), TG-HDL ratio (3.25 ± 1.48 vs. 2.72 ± 1.40, P < 0.001), and METS-IR (41.09 ± 10.55 vs. 37.68 ± 8.53, P < 0.001). Other demographic and clinical characteristics of the study participants are presented in Table 1. 10.1371/journal.pone.0343783.t001Table 1Demographic and clinical characteristics of the study participants.CharacteristicsTotalFertileInfertileP-valueN = 669N = 395N = 274 Age, years (SD) 32.33 (5.69)31.79 (5.65)33.11 (5.66) 0.003 AMH, ng/dL (SD) 4.89 (4.38)5.11 (4.68)4.58 (3.89)0.122BMI, kg/m2 (SD)25.17 (4.57)24.59 (4.19)26.02 (4.95) <0.001 Vitamin D, ng/dL (SD) 28.65 (14.54)28.75 (14.25)28.50 (14.97)0.829 TG, mg/dL (SD) 114.95 (43.07)108.95 (41.99)123.60 (43.20) <0.001 HDL, mg/dL (SD) 41.29 (4.97)42.13 (4.71)40.09 (5.10) <0.001 LDL, mg/dL (SD) 101.03 (48.54)98.03 (58.08)105.35 (29.44) <0.001 FBS, mg/dL (SD) 95.05 (25.05)92.09 (9.76)99.32 (36.98) <0.001 TyG (SD) 8.53 (0.43)8.45 (0.40)8.64 (0.45) <0.001 TyG-BMI (SD) 216.29 (49.68)209.24 (44.80)226.45 (54.48) <0.001 AIP (SD) 0.42 (0.19)0.39 (0.19)0.47 (0.19) <0.001 TG-HDL (SD) 2.94 (1.46)2.72 (1.40)3.25 (1.48) <0.001 METS-IR (SD) 39.07 (9.55)37.68 (8.53)41.09 (10.55) <0.001 Tobacco consumption (%) No 568 (84.90%)335 (84.81%)233 (85.04%)0.936 Yes 101 (15.10%)60 (15.19%)41 (14.96%) Acne (%) No 447 (66.82%)257 (65.06%)190 (69.34%)0.248 Yes 222 (33.18%)138 (34.94%)84 (30.66%) Alopecia (current or former) (%) No 508 (75.93%)292 (73.92%)216 (78.83%)0.144 Yes 161 (24.07%)103 (26.08%)58 (21.17%) Hirsutism (current or former) (%) No 340 (50.82%)201 (50.89%)139 (50.73%)0.968 Yes 329 (49.18%)194 (49.11%)135 (49.27%) Oligomenorreha (%) No 184 (27.50%)114 (28.86%)70 (25.55%)0.345 Yes 485 (72.50%)281 (71.14%)204 (74.45%) Polymenorreha (%) No 494 (73.84%)289 (73.16%)205 (74.82%)0.632 Yes 175 (26.16%)106 (26.84%)69 (25.18%) Hypermenorreha (%) No 484 (72.35%)295 (74.68%)189 (68.98%)0.105 Yes 185 (27.65%)100 (25.32%)85 (31.02%) Dysmenorreha (%) No 340 (50.82%)221 (55.95%)119 (43.43%) 0.001 Yes 329 (49.18%)174 (44.05%)155 (56.57%) Dyspareunia (%) No 479 (71.60%)306 (77.47%)173 (63.14%) <0.001 Yes 190 (28.40%)89 (22.53%)101 (36.86%)Acronyms: BMI: Body Mass Index, AMH: Anti-Müllerian Hormone, TyG: Triglyceride-Glucose Index, TyG-BMI: Triglyceride-Glucose Body Mass Index, AIP: Atherogenic Index of Plasma, TG-HDL: triglyceride to High-density lipoprotein ratio, METS-IR: Metabolic Score for Insulin Resistance. Demographic and clinical characteristics of the study participants. Acronyms: BMI: Body Mass Index, AMH: Anti-Müllerian Hormone, TyG: Triglyceride-Glucose Index, TyG-BMI: Triglyceride-Glucose Body Mass Index, AIP: Atherogenic Index of Plasma, TG-HDL: triglyceride to High-density lipoprotein ratio, METS-IR: Metabolic Score for Insulin Resistance. Infertility and atherogenic indices In the unadjusted model (Model 1), all indices demonstrated significant positive associations with infertility (Table 2). The TyG index showed a strong association (OR = 2.787, 95% CI: 1.914–4.057, P < 0.001), which remained robust after adjusting for age in Model 2 (OR = 2.716, 95% CI: 1.859–3.967, P < 0.001) and after further adjustment for LDL in Model 3 (OR = 2.901, 95% CI: 1.393–6.040, P = 0.004). 10.1371/journal.pone.0343783.t002Table 2Association between infertility and different atherogenic indices.IndexModel 1aModel 2bModel 3cOdds ratio (95% confidence interval)P-valueOdds ratio (95% confidence interval)P-valueOdds ratio (95% confidence interval)P-value TyG 2.787(1.914-4.057) < 0.001 2.716(1.859-3.967) < 0.001 2.901(1.393-6.040) 0.004 TyG-BMI 1.007(1.004-1.011) < 0.001 1.007(1.004-1.011) < 0.001 1.030(1.003-1.059) 0.028 AIP 8.677(3.833-19.640) < 0.001 8.440(3.710-19.196) < 0.001 9.065(1.722-47.721) 0.009 TG-HDL 1.294(1.159-1.444) < 0.001 1.286(1.151-1.436) < 0.001 1.164(0.947-1.432)0.148 METS-IR 1.039(1.021-1.057) < 0.001 1.039(1.021-1.057) < 0.001 1.162(1.031-1.309) 0.014 Acronyms: TyG: Triglyceride-Glucose Index, TyG-BMI: triglyceride glucose body mass index, AIP: Atherogenic Index of Plasma, TG-HDL: triglyceride to High-density lipoprotein ratio, METS-IR: Metabolic Score for Insulin Resistance.a. Unadjusted model.b. Adjusted for age.c. Adjusted for age, body mass index (BMI), and Low-density lipoprotein (LDL). Association between infertility and different atherogenic indices. Acronyms: TyG: Triglyceride-Glucose Index, TyG-BMI: triglyceride glucose body mass index, AIP: Atherogenic Index of Plasma, TG-HDL: triglyceride to High-density lipoprotein ratio, METS-IR: Metabolic Score for Insulin Resistance. a. Unadjusted model. b. Adjusted for age. c. Adjusted for age, body mass index (BMI), and Low-density lipoprotein (LDL). The TyG-BMI index was also significantly associated with infertility in the unadjusted (OR = 1.007, 95% CI: 1.004–1.011, P < 0.001) and age-adjusted model (OR = 1.007, 95% CI: 1.004–1.011, P < 0.001), also in the Model 3 (OR = 1.030, 95% CI: 1.003–1.059, P = 0.028). The AIP showed the largest point estimate of association among all indices. In the unadjusted model, the odds of infertility increased more than eightfold with each unit increase in AIP (OR = 8.677, 95% CI: 3.833–19.640, P < 0.001). This association remained highly significant in both the age-adjusted model (OR = 8.440, 95% CI: 3.710–19.196, P < 0.001) and the fully adjusted model (OR = 9.065, 95% CI: 1.722–47.721, P = 0.009). The TG-HDL ratio was significantly associated with infertility in Models 1 and 2 (OR = 1.294, 95% CI: 1.159–1.444, P < 0.001 and OR = 1.286, 95% CI: 1.151–1.436, P < 0.001, respectively), but the association weakened and lost significance in the fully adjusted model (OR = 1.164, 95% CI: 0.947–1.432, P = 0.148). Similarly, METS-IR was significantly associated with infertility in Models 1 and 2 (both OR = 1.039, 95% CI: 1.021–1.057, P < 0.001). After adjustment for LDL in Model 3, the association was also statistically significant (OR = 1.162, 95% CI: 1.031–1.309, P = 0.014). An RCS model was used to assess the non-linear relationship between the TG-HDL ratio and the odds of infertility among women with PCOS (Fig 1). The overall association was statistically significant (p < 0.001), with a significant non-linear component (p = 0.011). The curve illustrates a steep increase in the odds of infertility with rising TG-HDL values up to approximately 2.5. However, beyond a TG-HDL value of approximately 2.5, the 95% CI crosses the red dashed line (representing OR = 1), indicating that the association is no longer statistically significant in that range. Restricted cubic spline fitting for the association between TG-HDL ratio and female infertility. The red dashed horizontal line represents an odds ratio (OR) of 1, indicating no association. The green dashed vertical line indicates the threshold (approximately = 2.5) where the association loses statistical significance. The barcode plot on the X axis shows the sample size density across the TG-HDL ratio range. Predictive performance The predictive abilities of the evaluated metabolic indices for identifying infertility among women with PCOS were assessed using receiver operating characteristic (ROC) curve analysis. As illustrated in Fig 2, the area under the curve (AUC) values were highest for the AIP and the TG-HDL, both with an AUC of 0.625, indicating modest discriminatory power. The TyG index also demonstrated a comparable performance with an AUC of 0.624. The METS-IR score yielded a slightly lower AUC of 0.601, while the TyG-BMI index had the lowest predictive value among the evaluated indices, with an AUC of 0.598. ROC curves for atherogenic indices to predict female infertility. The AUC values observed for all indices ranged from 0.598 to 0.625, indicating poor to modest discriminative ability. These findings suggest that, when used individually, the evaluated metabolic indices have limited capacity to distinguish between infertile and fertile women with PCOS. Discussion Principal findings In this cross-sectional study of 669 women with polycystic ovary syndrome (PCOS), we evaluated the association and predictive performance of several metabolic indices—including TyG, TyG-BMI, AIP, TG-HDL, and METS-IR—in relation to infertility. All indices were significantly higher in infertile women compared to their fertile counterparts and showed positive associations with infertility in unadjusted, age-adjusted, and fully adjusted logistic regression models. Notably, AIP demonstrated the largest point estimate of association, with an odds ratio exceeding 8, even after full adjustment for confounders. Despite these statistically significant associations, the predictive performance of all indices was modest, with AUC values ranging from 0.598 to 0.625. These results indicate that, although metabolically informative, none of the evaluated indices are suitable as standalone tools for clinical prediction or screening of infertility in women with PCOS. Biological pathways IR can lead to several problems that affect fertility in women with PCOS. IR causes high levels of insulin, which can disturb the balance of hormones needed for normal ovulation [20,21]. In addition to this, IR increases inflammation in the body by raising levels of cytokines such as TNF-α and IL-6. These inflammatory substances can negatively affect how the ovaries work and reduce the quality of the eggs [22]. IR can also cause oxidative stress, which damages the cells in the ovaries and makes it harder for good-quality eggs to develop [23]. These problems, together with hormonal imbalance, can make it more difficult for women with PCOS to become pregnant. Fat tissue also plays an important role in this process. Besides storing energy, fat tissue produces hormones that affect reproduction. In PCOS, too much fat—especially around the abdomen—can change the levels of hormones like leptin and adiponectin. High leptin levels and low adiponectin levels can both interfere with insulin sensitivity and hormone regulation [24]. This creates a cycle that worsens both metabolic and reproductive problems [21]. Also, high levels of fats in the ovaries can damage the cells that support egg development, leading to poor egg quality [25]. These biological changes may help explain the link between atherogenic and insulin resistance indices and infertility in PCOS. Results in the context of what is known Our findings are broadly consistent with previous research exploring the association between metabolic indices and female infertility, though our study adds to the literature by focusing specifically on women with PCOS and evaluating a more comprehensive range of indices. Li et al. (2025), analyzing data from the NHANES study, found a significant association between the METS-IR and infertility, with adjusted odds ratios (aORs) consistently at 1.02 (95% CI: 1.01–1.04), even after controlling for a wide range of sociodemographic and clinical confounders [26]. Our study also identified a significant association between METS-IR and infertility in unadjusted and age-adjusted models; additionally, the association kept its significance after further adjustment for BMI and LDL. Similarly, Liu et al. (2025) and Kong et al. (2024) demonstrated significant associations between the Cardiometabolic Index (CMI) and infertility, with adjusted ORs of 1.27 and 1.12, respectively, though predictive performance was not reported [27,28]. While our study did not evaluate CMI specifically, we included closely related indices such as TG-HDL and AIP, which similarly reflect lipid-glucose interactions. Zhuang et al. (2024) assessed the TyG index and reported an adjusted OR of 1.51 (95% CI: 1.14–2.00) with a modest AUC of 0.56 [29]. Our findings confirm the association of TyG with infertility, showing a stronger effect size (fully adjusted OR = 2.901) and a higher AUC of 0.624, though still in the modest range. The greater strength of association in our study may reflect the higher metabolic burden of PCOS patients compared to the general population examined in NHANES studies. Li et al. (2024) focused on the estimated glucose disposal rate (eGDR), an insulin sensitivity index, and found a significant inverse association with infertility (adjusted OR = 0.86), along with an AUC of 0.632 [30]. While we did not assess eGDR, our findings on METS-IR—a related insulin resistance marker—are directionally consistent, albeit with slightly lower predictive value (AUC = 0.601). Notably, Xia et al. (2023) investigated both TyG and TyG-BMI indices, reporting adjusted ORs of 1.37 and 1.01, respectively, and AUCs of 0.62 and 0.68 [31]. In our PCOS participants, we observed similar associations for both indices, though TyG-BMI had the lowest AUC (0.598), suggesting that the added value of BMI in TyG-BMI may be limited in populations already at high risk for metabolic dysfunction. Importantly, none of the reviewed studies included the AIP, which in our analysis emerged as the strongest predictor of infertility, with an adjusted OR of 9.065 (95% CI: 1.722–47.721) and an AUC of 0.625. This highlights the novelty of our study in evaluating AIP in the context of reproductive outcomes. However, consistent with previous literature, the overall predictive performance of all indices—ranging from AUCs of 0.598 to 0.625—was modest, underscoring the limited clinical utility of these markers when used in isolation. Table 3- Findings of studies for the association between different atherogenic and insulin resistance indices and female infertility. 10.1371/journal.pone.0343783.t003Table 3Findings of studies for the association between different atherogenic and insulin resistance indices and female infertility.Author (year)PopulationInvestigated IndicesAssociationPredictive PerformanceLi et al. (2025) [26]1,541 participants from the National Health and Nutrition Examination Survey (NHANES) from 2013 to 2018. Those aged over 45 or under 18 years, and those with missing data on METS-IR or infertility were excluded.METS-IR• Unadjusted: OR = 1.02 (1.01–1.04)***• Adjusted for age and ethnicity: OR = 1.02 (1.01–1.03)**• Further adjusted for education, poverty-income ratio, marital status, drinking, blood cotinine, dyslipidemia, diabetes, hypertenstion, mesntural status, pelvic inflammatory disease, contraceptive pill use, female hormone use: OR = 1.02 (1.01–1.04)**Not disclosedLiu et al. (2025) [27]3,613 participants from the NHANES database from 2013 to 2020. Individuals aged < 20 years or> 45 years, lacked information on fertility status, and incomplete CMI measurements were excluded.CMI• Adjusted for age, race, education: OR = 1.34 (1.16–1.55)***• Adjusted for age, race, education, ratio of income; marital status, smoke; hypertension; diabetes: OR = 1.27 (1.08–1.49)**Not disclosedZhuang et al. (2024) [29]1,556 participants from the NHANES database from 2013 to 2020. Participants lacking data on TyG index, fertility information, and participants older than 45 years or younger than 18 years were excluded.TyG• Unadjusted: OR = 1.41 (1.12–1.79)**• Adjusted for age and race: OR = 1.45 (1.14–1.85)**• Adjusted for age, ratio of family income to poverty, race, education level, marital status, smoked at least 100 cigarettes, had at least 12 alcohol drinks/1 year, ever treated for a pelvic infection/PID, ever taken birth control pills, had regular periods in past 12 months: OR = 1.51 (1.14–2.00)**AUC = 0.56Li et al. (2024) [30]2,541 participants from the NHANES database from 2013 to 2020. Participants aged < 18 or > 45 years, without infertility questionnaire data, without complete eGDR data, and missing data on covariates information were excluded.eGDR• Unadjusted: OR = 0.85 (0.80–0.90)***• Adjusted for age, race/ethnicity, and education: OR = 0.87 (0.81–0.93)***• Adjusted for age, race/ethnicity, education, poverty income ratio, marital status, smoking, drinking, hemoglobin, total cholesterol, diabetes, regular period and pelvic inflammatory disease, adrenocortical insufficiency and sex hormone dysfunction: OR = 0.86 (0.80–0.94)***AUC = 0.632Kong et al. (2024) [28]1,720 participants from the NHANES database from 2013 to 2020. Minor (age < 18) participants excluded, and people with full CMI and infertility data were picked for inclusion.CMI• Unadjusted: OR = 1.10 (1.01–1.21)*• Adjusted for age and race: OR = 1.10 (1.01–1.21)*• Adjusted for age, race, ratio of family income to poverty, education level, marital status, diabetes, cardiovascular disease history, smoked at least 100 cigarettes, age when first menstrual period occurred, ever taken birth control pills, ever treated for a pelvic infection/pelvic inflammatory disease, had regular periods in past 12 months: OR = 1.12 (1.01–1.24)*Not disclosedXia et al. (2023) [31]1,043 participants from the NHANES database from 2013 to 2020. Participants aged < 18 or > 36 years, without infertility data, with missing BMI, triglyceride, serum insulin and fasting glucose data, and missing data were excluded.TyG and TyG-BMITyG:• Unadjusted: OR = 2.00 (1.43–2.78)***• Adjusted for age: OR = 1.80 (1.29–2.52)***• Adjusted for age, marital status, education, LDL, hypertension, diabetes: OR = 1.37 (0.93–2.01)TyG-BMI:• Unadjusted: OR = 1.01 (1.00–1.01)***• Adjusted for age: OR = 1.01 (1.00–1.01)***• Adjusted for age, marital status, education, LDL, hypertension, diabetes: OR = 1.01 (1.00–1.01)***AUC TyG = 0.62AUC TyG-BMI = 0.68Acronyms: BMI: Body Mass Index, TyG: Triglyceride-Glucose Index, TyG-BMI: triglyceride glucose body mass index, METS-IR: Metabolic Score for Insulin Resistance, eGDR: Estimated glucose disposal rate, CMI: Cardiometabolic Index.* P-value < 0.05, ** P-value < 0.01, *** P-value < 0.001. Findings of studies for the association between different atherogenic and insulin resistance indices and female infertility. Acronyms: BMI: Body Mass Index, TyG: Triglyceride-Glucose Index, TyG-BMI: triglyceride glucose body mass index, METS-IR: Metabolic Score for Insulin Resistance, eGDR: Estimated glucose disposal rate, CMI: Cardiometabolic Index. * P-value < 0.05, ** P-value < 0.01, *** P-value < 0.001. Clinical implications Although the discriminative performance of the metabolic indices examined in this study was modest, our findings suggest that unfavorable lipid-related profiles may help identify subgroups of women with PCOS who are at increased risk of infertility. These indices are readily available in routine clinical practice and may serve as adjunctive markers for risk stratification and early counseling rather than as standalone predictive tools. From a clinical perspective, recognition of adverse metabolic patterns in women with PCOS may support timely lifestyle interventions as part of a more general fertility-focused management strategy. However, these indices should not be used in isolation for clinical prediction, and their utility should be confirmed in prospective studies. Strengths and limitations This study has several notable strengths. First, it is among the few to comprehensively assess multiple atherogenic and insulin resistance indices—including AIP, TyG, TyG-BMI, TG-HDL, and METS-IR—in relation to infertility specifically within a PCOS population, rather than the general population. Given the metabolic vulnerability of women with PCOS, this targeted approach enhances the clinical relevance of our findings. Second, the use of a relatively large and well-defined sample (n = 669) from a tertiary care center adds strength and improves the precision of our estimates. Moreover, we assessed predictive performance using ROC curve analysis, offering insight into the clinical utility of these indices. However, our study also has limitations. Its cross-sectional design precludes causal inference between metabolic indices and infertility. Although infertility status was clinically documented, a detailed etiologic workup was not uniformly available for all participants; therefore, residual misclassification of infertility causes cannot be fully excluded. Moreover, important potential confounders such as dietary patterns, physical activity, and other lifestyle factors were not available in the medical records and therefore could not be adjusted for. Similarly, detailed reproductive factors were not comprehensively available to assess. Residual confounding from these unmeasured factors may have influenced the observed associations. Also, selection bias may be present, as the study population was drawn from a tertiary care center, which may overrepresent women with more severe metabolic or reproductive manifestations of PCOS. Finally, while we evaluated several indices, some newer or less commonly used markers (e.g., eGDR, CMI) were not included, which may limit comparability with all prior research. Conclusion In this cross-sectional study of women with polycystic ovary syndrome, we found that several metabolic indices—including AIP, TyG, TyG-BMI, TG-HDL, and METS-IR—were significantly associated with infertility, with AIP demonstrating the largest point estimate of association. Although several metabolic indices—particularly AIP—were independently associated with infertility, their discriminatory performance was limited. Therefore, these indices should not be used as standalone clinical predictors. Future research should focus on integrated, multifactorial models combining metabolic markers with reproductive hormones, ovulatory function, and lifestyle factors. Prospective cohort studies are also needed to establish temporal and causal relationships between metabolic health and infertility. 19 Dec 2025 -->PONE-D-25-55841-->-->Association between different atherogenic and insulin resistance indices and infertility in polycystic ovary syndrome patients-->-->PLOS One Dear Dr. Abiri, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Dear authors, as you can see, the reviewers have requested substantial revisions to your manuscript. We are certainly willing to reconsider a revised submission, but please know that this is not preliminary acceptance of your paper. When returning your revised manuscript, please be sure to include a point-by-point summary of the suggestions of the reviewers that specifies how and where in the text you have addressed the suggestions. Please submit your revised manuscript by Feb 02 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:--> A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Ricardo Ney Oliveira Cobucci, Ph.D Academic Editor PLOS One Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf. 2. In the online submission form you indicate that your data is not available for proprietary reasons and have provided a contact point for accessing this data. Please note that your current contact point is a co-author on this manuscript. According to our Data Policy, the contact point must not be an author on the manuscript and must be an institutional contact, ideally not an individual. Please revise your data statement to a non-author institutional point of contact, such as a data access or ethics committee, and send this to us via return email. Please also include contact information for the third party organization, and please include the full citation of where the data can be found. 3. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section. 4. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions -->Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. --> Reviewer #1: Partly Reviewer #2: Yes ********** -->2. Has the statistical analysis been performed appropriately and rigorously? --> Reviewer #1: Yes Reviewer #2: Yes ********** -->3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.--> Reviewer #1: No Reviewer #2: Yes ********** -->4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.--> Reviewer #1: Yes Reviewer #2: No ********** -->5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)--> Reviewer #1: This cross-sectional study examines the association between five metabolic indices (TyG, TyG-BMI, AIP, TG-HDL, METS-IR) and infertility in 669 Iranian women with PCOS. The authors report that all indices were significantly higher in infertile women, with AIP showing the strongest association (adjusted OR = 9.065). However, ROC analysis revealed modest predictive performance (AUCs 0.598–0.625), suggesting limited standalone clinical utility. The study addresses a relevant clinical question and is methodologically sound in many respects. However, several issues must be addressed: 1. TyG-BMI formula in the Methods --> it should be TyGxBMI not TgXBMI. 2. Specify how “unsuccessful conception” was documented and whether other causes of infertility were considered. 3. Given the modest AUCs, emphasize that these indices are not yet suitable for standalone clinical prediction. 4. Expand limitations: Address potential unmeasured confounders (e.g., diet, physical activity, detailed infertility workup). 5. Consider adding a sensitivity analysis: Excluding women with very high TG-HDL ratios (>2.5) where the association became non-significant. Figure 1: 1. Clarity of Red Dashed Line: The caption should explicitly state that the red dashed line represents OR = 1 (no association). 2. Threshold Annotation: Adding a vertical dotted line at TG-HDL ≈ 2.5 with a brief note (e.g., “threshold”) would help readers quickly interpret the inflection point. Figure 2: 1. The legend lists “TG_HDL” and “TyG_HDL.” However“TyG_HDL” is not described in the text. 2. Some lines are very close together (AIP, TG-HDL). Consider using dashed/dotted styles or clearer color differentiation. 3. It would be helpful to add AUC values in the legend (e.g., “AIP (AUC = 0.625)”) for immediate comparison. 4. “BMI” is included in the ROC but not discussed in the predictive performance results. Either explain its inclusion or remove it to avoid distraction. Reviewer #2: PONE-D-25-55841 I am writing to express my opininion on Association between different atherogenic and insulin resistance indices and infertility in polycystic ovary syndrome patients which submitted in plos one journal. This study suffred from lack of novelity, its not sutible for publication untill major revision. Authors failed to picture the rationality of this study? What is main novelity? Previous study answer this question how you fill the gap? How many women you excluded due to the exclusion criteria? How were the techniues of assessments , kits, methodes… How was diagnostic criteria of PCOS? What is definition of infertility? It was better to have a control group for comparison. Please discuss about any pollsible bias of study. What is clinical implication of study? Editor advised to check the usig of AI. ********** -->6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.--> Reviewer #1: No Reviewer #2: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. 31 Jan 2026 Dear Dr. Ricardo Ney Oliveira Cobucci, We sincerely appreciate the time and effort you and the reviewer have dedicated to evaluating our manuscript, "Association between different atherogenic and insulin resistance indices and infertility in polycystic ovary syndrome patients" (Manuscript ID: PONE-D-25-55841). We are grateful for the constructive feedback, which has helped us improve the quality of our work, and accept our sincerest apologies for the late response, since, because of the total internet shutdown in Iran, we were not able to communicate. We have carefully addressed all the comments and suggestions provided by the reviewer. Below, we provide a point-by-point response to each remark, detailing the revisions made in the revised manuscript. All changes have been highlighted in the revised version for easy reference in yellow. Reviewer #1 We are truly grateful for your kind and encouraging words. Your positive feedback means a great deal to our team and reinforces our commitment to further research in this area. Thank you for taking the time to review our work so thoughtfully. Comment 1: "TyG-BMI formula in the Methods --> it should be TyGxBMI not TgxBMI.” Response 1: We corrected this typo. Comment 2: "Specify how “unsuccessful conception” was documented and whether other causes of infertility were considered.” Response 2: Infertility status was determined based on documentation in medical records and defined as failure to achieve pregnancy after at least 12 months of regular unprotected intercourse, as recorded during routine clinical assessments by treating gynecologists. Classification was therefore not based solely on self-report. Male factor infertility was explicitly excluded. Other female causes of infertility unrelated to PCOS were considered when information was available in medical records; however, infertility was classified as all-cause infertility within a PCOS population. We have clarified this point in the Measurements and Tools section (lines 110-117) and acknowledged the potential for residual misclassification in the Limitations section (lines 343-344). Comment 3: "Given the modest AUCs, emphasize that these indices are not yet suitable for standalone clinical prediction.” Response 3: We agree with the reviewer and thank them for this valuable suggestion. We have revised the Results (lines 243-246), Discussion (lines 258-262), and Conclusion (lines 359-361) sections to explicitly state that these indices are not suitable as standalone tools for infertility prediction in women with PCOS and should be interpreted as adjunctive metabolic markers rather than independent screening instruments. Comment 4: "Expand limitations: Address potential unmeasured confounders (e.g., diet, physical activity, detailed infertility workup).” Response 4: We have expanded the Strengths and Limitations section (lines 344-348) to explicitly acknowledge the potential influence of unmeasured confounders (as you asked for diet, physical activity, and detailed infertility workup) and their possible role in the residual confounding. Comment 5: "Consider adding a sensitivity analysis: Excluding women with very high TG-HDL ratios (>2.5) where the association became non-significant.” Response 5: We thank the reviewer for this insightful suggestion. To address potential non-linearity and the influence of extreme values, we modeled the association between the TG–HDL ratio and infertility using restricted cubic spline analysis, which provides a flexible and statistically appropriate assessment without imposing arbitrary cut points. The spline analysis demonstrated a significant overall and non-linear association, with loss of statistical significance at higher TG–HDL values. Importantly, as illustrated in the spline plot (barcode plot on the X axis of Fig. 1), the number of observations decreases substantially at TG–HDL ratios above approximately 2.5, which may partly explain the widening confidence intervals and loss of statistical significance in this range, rather than a true absence of association. Given that non-linearity has already been formally evaluated and that post hoc exclusion based on a threshold may introduce selection bias, we chose not to perform an additional sensitivity analysis at this stage. However, if the reviewer or editor considers such an analysis essential, we would be pleased to perform it and report the results in a subsequent round of revisions or as supplementary material. Comments on Figure 1: Comment 1: Clarity of Red Dashed Line: The caption should explicitly state that the red dashed line represents OR = 1 (no association). Response 1: We have revised the caption of Figure 1 accordingly (lines 230-233). Comment 2: Threshold Annotation: Adding a vertical dotted line at TG-HDL ≈ 2.5 with a brief note (e.g., “threshold”) would help readers quickly interpret the inflection point. Response 2: We have revised Figure 1 accordingly. Comments on Figure 2: Comment 1: “The legend lists “TG_HDL” and “TyG_HDL.” However“TyG_HDL” is not described in the text.” Response 1: We have removed the TyG-HDL from Figure 2. Comment 2: “Some lines are very close together (AIP, TG-HDL). Consider using dashed/dotted styles or clearer color differentiation.” Response 2: We have made necessary edits and replaced Fig 2 with a new plot. Comment 3: “It would be helpful to add AUC values in the legend (e.g., “AIP (AUC = 0.625)”) for immediate comparison.” Response 3: We have added the AUC values in the new plot. Comment 4: “BMI” is included in the ROC but not discussed in the predictive performance results. Either explain its inclusion or remove it to avoid distraction.” Response 4: We have removed the BMI from the new plot. Reviewer #2 Thank you for taking the time to review our work. We’re grateful for your guidance throughout the review process. Comment 1: “Authors failed to picture the rationality of this study? What is main novelity? Previous study answer this question how you fill the gap?” Response 1: The novelty of our study lies in the comprehensive, PCOS-specific evaluation of multiple metabolic indices, including the first assessment of AIP in relation to infertility, along with non-linear modeling and ROC analysis to assess clinical relevance. While we mentioned these in the last paragraph of our Introduction section, we have revised the text (lines 79-89) to more explicitly highlight these gaps and to clarify the novelty of our study. Comment 2: “How many women you excluded due to the exclusion criteria?” Response 4: We have clarified the number of participants excluded (n=335) based on the predefined exclusion criteria in the Study Design and Participants section (lines 160-161). Comment 3: “How were the techniues of assessments , kits, methodes…” Response 4: We have revised the Measurements and Tools section to provide additional details on the assessment techniques and methods (lines 103-109). Comment 4: “How was diagnostic criteria of PCOS?” Response 4: We have clarified the diagnostic criteria of PCOS in the Measurements and Tools section (lines 118-122). Comment 5: “What is definition of infertility?” Response 5: We have clarified the definition of infertility in the Measurements and Tools section (lines 110-117). Comment 6: “It was better to have a control group for comparison.” Response 6: The primary objective of this study was to examine the association between metabolic indices and infertility within a population of women with PCOS, rather than to compare women with and without PCOS. Accordingly, we used an internal comparison between infertile (cases) and fertile (control) women with PCOS to minimize confounding related to the diagnosis of PCOS itself and to better characterize metabolic heterogeneity within this high-risk group. While inclusion of a non-PCOS control group may be informative for other research questions, it was beyond the scope of the present study. Comment 7: “Please discuss about any pollsible bias of study.” Response 7: We have expanded the Strengths and Limitations section to explicitly discuss potential sources of bias(including selection bias related to the tertiary-care setting, residual confounding from unmeasured lifestyle and reproductive factors, etc.) (lines 344-351). Comment 8: “What is clinical implication of study?” Response 8: We have added a Clinical Implications subsection to the Discussion to clarify the potential relevance of our findings (lines 318-327). Comment 9: “Editor advised to check the usig of AI.” Response 9: We confirm that no artificial intelligence tools were used for data collection, statistical analysis, result generation, or scientific interpretation in this study. Any language editing, where applicable, was limited to improving grammar and clarity, and all content was reviewed and approved by the authors. Sincerely, Dr. Amene Abiri Submitted filename: response 2026-01-07.pdf 11 Feb 2026 Association between different atherogenic and insulin resistance indices and infertility in polycystic ovary syndrome patients PONE-D-25-55841R1 Dear Dr. Abiri, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Ricardo Ney Oliveira Cobucci, Ph.D Academic Editor PLOS One Additional Editor Comments (optional): Congratulations. Reviewers' comments: Reviewer's Responses to Questions -->Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.--> Reviewer #1: All comments have been addressed ********** -->2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. --> Reviewer #1: Yes ********** -->3. Has the statistical analysis been performed appropriately and rigorously? --> Reviewer #1: Yes ********** -->4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.--> Reviewer #1: Yes ********** -->5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.--> Reviewer #1: Yes ********** -->6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)--> Reviewer #1: (No Response) ********** -->7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.--> Reviewer #1: No ********** PONE-D-25-55841R1 PLOS One Dear Dr. Abiri, I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team. At this stage, our production department will prepare your paper for publication. This includes ensuring the following: * All references, tables, and figures are properly cited * All relevant supporting information is included in the manuscript submission, * There are no issues that prevent the paper from being properly typeset You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps. Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing. If we can help with anything else, please email us at customercare@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of PROFESSOR Ricardo Ney Oliveira Cobucci Academic Editor PLOS One